The existing research aimed to explore triclabendazole effect (10 mg/kg b.wt., orally ) on disposition kinetic of tildipirosin (4 mg/kg b.wt) administered by intravenous or intramuscular routes in goats. Serum tildipirosin concentration was measured using microbiological technique by Bacillus  subtilis. The concentration-time curve of tildipirosin was described via two compartment open model. Concomitant administration with triclabendazole decreased tildipirosin concentrations in serum post IV and IM injection.
After IV administration, serum tildipirosin concentration at zero time (Co) showed lower in the triclabendazole pretreated goat group. The administration of triclabendazole significantly increased the tildipirosin distribution rate constant (alpha), the apparent peripheral compartment volume (V2); distribution volume at steady state (Vdss), total body clearance (CL) and inter-compartmental clearances (CL2) in the second group compared with first group. On the other hand, triclabendazole potentially reduced the half-life of distribution (t1/2 Alpha), half- life of elimination (t1/2Beta), area under curve (AUC0-t), and mean residence time expressed as MRT in the triclabendazole co-administered group.
Following intramuscular injection, absorption half-life and corresponding t max exposed fast tildipirson absorption rate. Maximum serum concentration (Cmax) and area under the curve of tildipirosin showed significant decline of triclabendazole co-administered group compared with tildipirosin alone. Both t1/2 beta and MRT were decreased post I/M injection in the tildipirosin-triclabendazole group.Simultaneous administration of triclabendazole and tildipirosin caused significant variations in tildipirosin disposition kinetic. The interactions between the two drugs have clinical importance and so require tildipirosin dosage monitoring.